Alkermes (ALKS) Receivables - Net (2011 - 2026)
Alkermes' (ALKS) quarterly Receivables - Net came in at $407.6 million in Q1 2026, up 27.9% year-on-year from $318.7 million in Q1 2025, and up 22.04% on a QoQ basis from $334.0 million in Q4 2025.
Alkermes (ALKS) Receivables - Net (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Receivables - Net data on file, last reported at $407.6 million in Q1 2026.
- On a quarterly basis, Receivables - Net rose 27.9% year-over-year to $407.6 million in Q1 2026; TTM through Mar 2026 was $407.6 million, a 27.9% increase from a year earlier, with the FY2025 full-year figure at $334.0 million, up 6593.89% from the prior year.
- Receivables - Net for Q1 2026 stood at $407.6 million, up from $334.0 million in the prior quarter.
- Over the last five years, Receivables - Net for ALKS reached as high as $407.6 million in Q1 2026 and fell as low as $706000.0 in Q4 2023.
- Historically, Receivables - Net has averaged $181.9 million across 5 years, with a median of $257.2 million in 2022.
- Across the five-year window, Receivables - Net tumbled 98.96% in 2024 and surged 6593.89% in 2025, its largest moves.
- Year by year, Receivables - Net stood at $8.9 million in 2022, then tumbled by 92.09% to $706000.0 in 2023, then jumped by 606.8% to $5.0 million in 2024, then jumped by 6593.89% to $334.0 million in 2025, then grew by 22.04% to $407.6 million in 2026.
- Per Business Quant data, the three most recent Receivables - Net figures were $407.6 million in Q1 2026, $334.0 million in Q4 2025, and $354.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 407.63 Mn |
| Mar 31, 2026 | 407.63 Mn |
| Dec 31, 2025 | 334.03 Mn |
| Dec 31, 2025 | 334.03 Mn |
| Sep 30, 2025 | 354.39 Mn |
| Sep 30, 2025 | 354.39 Mn |
| Jun 30, 2025 | 1.42 Mn |
| Jun 30, 2025 | 1.42 Mn |
| Mar 31, 2025 | 318.70 Mn |
| Mar 31, 2025 | 318.70 Mn |
| Dec 31, 2024 | 4.99 Mn |
| Dec 31, 2024 | 4.99 Mn |
| Sep 30, 2024 | 367.21 Mn |
| Sep 30, 2024 | 367.21 Mn |
| Jun 30, 2024 | 3.49 Mn |
| Jun 30, 2024 | 3.49 Mn |
| Mar 31, 2024 | 315.85 Mn |
| Mar 31, 2024 | 315.85 Mn |
| Dec 31, 2023 | 706,000.00 |
| Dec 31, 2023 | 706,000.00 |